Circulating endothelial progenitor cells in gynaecological cancer

Yoon Byoung Kim, Ye Won Chung, Hyo Sook Bae, Jae Kwan Lee, Nak Woo Lee, Kyu Wan Lee, Jae Yun Song

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers. Methods: Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45-/CD34+/CD133+/vascular endothelial growth factor receptor 2 (VEGFR2)+ cells. Results: In total, 28 participants were enrolled. Circulating EPCs were present at higher frequencies (and in greater absolute numbers) in patients with cervical or ovarian cancer (n=14) than in controls (n=14). Concurrent chemoradiation therapy or surgery significantly reduced the frequency and number of EPCs in patients with gynaecological cancer, compared with pretreatment levels. Conclusions: EPC levels decline throughout cancer treatment; their measurement may therefore be a useful surrogate marker to monitor treatment response.

Original languageEnglish
Pages (from-to)293-299
Number of pages7
JournalJournal of International Medical Research
Volume41
Issue number2
DOIs
Publication statusPublished - 2013 Jun 4

Fingerprint

Endothelial cells
Neoplasms
Oncology
Uterine Cervical Neoplasms
Ovarian Neoplasms
Healthy Volunteers
Vascular Endothelial Growth Factor Receptor-2
Flow cytometry
Cell Separation
Therapeutics
Surgery
Fluorescent Antibody Technique
Endothelial Progenitor Cells
Flow Cytometry
Blood
Cell Count
Biomarkers
Staining and Labeling

Keywords

  • CD133
  • CD34
  • CD45
  • Cervical cancer
  • Circulating endothelial progenitor cells
  • Ovarian cancer
  • Vegfr2

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this

Circulating endothelial progenitor cells in gynaecological cancer. / Kim, Yoon Byoung; Chung, Ye Won; Bae, Hyo Sook; Lee, Jae Kwan; Lee, Nak Woo; Lee, Kyu Wan; Song, Jae Yun.

In: Journal of International Medical Research, Vol. 41, No. 2, 04.06.2013, p. 293-299.

Research output: Contribution to journalArticle

Kim, Yoon Byoung ; Chung, Ye Won ; Bae, Hyo Sook ; Lee, Jae Kwan ; Lee, Nak Woo ; Lee, Kyu Wan ; Song, Jae Yun. / Circulating endothelial progenitor cells in gynaecological cancer. In: Journal of International Medical Research. 2013 ; Vol. 41, No. 2. pp. 293-299.
@article{72d056fd2cbd49229cc769f800afb2e8,
title = "Circulating endothelial progenitor cells in gynaecological cancer",
abstract = "Objectives: To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers. Methods: Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45-/CD34+/CD133+/vascular endothelial growth factor receptor 2 (VEGFR2)+ cells. Results: In total, 28 participants were enrolled. Circulating EPCs were present at higher frequencies (and in greater absolute numbers) in patients with cervical or ovarian cancer (n=14) than in controls (n=14). Concurrent chemoradiation therapy or surgery significantly reduced the frequency and number of EPCs in patients with gynaecological cancer, compared with pretreatment levels. Conclusions: EPC levels decline throughout cancer treatment; their measurement may therefore be a useful surrogate marker to monitor treatment response.",
keywords = "CD133, CD34, CD45, Cervical cancer, Circulating endothelial progenitor cells, Ovarian cancer, Vegfr2",
author = "Kim, {Yoon Byoung} and Chung, {Ye Won} and Bae, {Hyo Sook} and Lee, {Jae Kwan} and Lee, {Nak Woo} and Lee, {Kyu Wan} and Song, {Jae Yun}",
year = "2013",
month = "6",
day = "4",
doi = "10.1177/0300060513476999",
language = "English",
volume = "41",
pages = "293--299",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "2",

}

TY - JOUR

T1 - Circulating endothelial progenitor cells in gynaecological cancer

AU - Kim, Yoon Byoung

AU - Chung, Ye Won

AU - Bae, Hyo Sook

AU - Lee, Jae Kwan

AU - Lee, Nak Woo

AU - Lee, Kyu Wan

AU - Song, Jae Yun

PY - 2013/6/4

Y1 - 2013/6/4

N2 - Objectives: To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers. Methods: Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45-/CD34+/CD133+/vascular endothelial growth factor receptor 2 (VEGFR2)+ cells. Results: In total, 28 participants were enrolled. Circulating EPCs were present at higher frequencies (and in greater absolute numbers) in patients with cervical or ovarian cancer (n=14) than in controls (n=14). Concurrent chemoradiation therapy or surgery significantly reduced the frequency and number of EPCs in patients with gynaecological cancer, compared with pretreatment levels. Conclusions: EPC levels decline throughout cancer treatment; their measurement may therefore be a useful surrogate marker to monitor treatment response.

AB - Objectives: To compare the frequency and absolute numbers of circulating endothelial progenitor cells (EPCs) in healthy control subjects and patients with gynaecological cancer, and to test the hypothesis that cancer treatment lowers EPC numbers. Methods: Patients with cervical or ovarian cancer and healthy control subjects provided peripheral blood samples for the isolation of mononuclear cells. EPCs were identified by quadruple immunofluorescence staining and flow cytometry as CD45-/CD34+/CD133+/vascular endothelial growth factor receptor 2 (VEGFR2)+ cells. Results: In total, 28 participants were enrolled. Circulating EPCs were present at higher frequencies (and in greater absolute numbers) in patients with cervical or ovarian cancer (n=14) than in controls (n=14). Concurrent chemoradiation therapy or surgery significantly reduced the frequency and number of EPCs in patients with gynaecological cancer, compared with pretreatment levels. Conclusions: EPC levels decline throughout cancer treatment; their measurement may therefore be a useful surrogate marker to monitor treatment response.

KW - CD133

KW - CD34

KW - CD45

KW - Cervical cancer

KW - Circulating endothelial progenitor cells

KW - Ovarian cancer

KW - Vegfr2

UR - http://www.scopus.com/inward/record.url?scp=84878348242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878348242&partnerID=8YFLogxK

U2 - 10.1177/0300060513476999

DO - 10.1177/0300060513476999

M3 - Article

VL - 41

SP - 293

EP - 299

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - 2

ER -